PVEK shows promise treating rare blood cancer

A new antibody-drug conjugate, pivekimab sunirine (PVEK), showed high response rates in a trial for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare blood cancer. The Phase I/II study found an 85% overall response rate, including a 70% complete response rate, in newly diagnosed BPDCN patients. The median overall survival was 16.6 months, suggesting PVEK could become a new standard treatment. The trial, presented at the ASCO Annual Meeting, involved 84 patients. PVEK targets CD123 on cancer cells, offering a potential improvement over current treatments.